Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the best affordable biotech stocks to invest in now. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) reported its fiscal Q2 2025 results on August 5, with total revenue for the quarter reaching approximately $101.7 million. This included net product sales of$58.9 million and contract revenues from collaborations of $42.7 million. The company also generated$59.6 million in net income. Following the results, Jefferies analyst Eun Yang maintained a Hold ratin ...